Blog | HemaCare

HemaCare Aids Strategy for Boosting Gene Therapy Efficiency

May 21, 2019 10:06:00 AM / by Nancy Andon, MSc posted in Gene Therapy, bone marrow stem cells, CD34, Stem Cells, mobilized peripheral blood

0 Comments

An independent publication cites the use of bone marrow and mobilized peripheral blood sourced from HemaCare in a study aimed at improving the efficiency of resource consumption in gene therapy.

The publication, published in the journal Molecular Therapy, focuses on the use of lentiviral vector (LV) to introduce corrected versions of defective genes into stem cells. The goal of gene therapy is to transplant these stem cells into people suffering from genetic disease, in hopes of restoring the function of the faulty gene. One of the main challenges in this clinical strategy is the cost; substantial amounts of LV are needed to modify a therapeutically effective dose of stem cells.

Read More

Can Stem Cells Be A Game Changer for MS Patients?

Apr 2, 2019 10:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in CD34, stem cell treatment, Stem Cells

0 Comments

Stem-cells and MS are widely discussed, but we might be finally getting closer to stem-cell treatments for MS patients.

Stem cell therapies are investigated for their potential to provide long-lasting or permanent remission of multiple sclerosis (MS) signs and symptoms. Many patients are well-informed of the potential of stem cell therapy for MS, and many seek treatments abroad that are promoted to give positive or curative outcomes. There are also clinics in the US that provide treatments that are outside of FDA-approved uses. The only FDA-approved, stem-cell based products used in the US consist of CD34+ stem cells derived from cord blood.

Read More

Stem Cell Method Sheds Light on Heart Disease

Jul 2, 2018 9:59:00 AM / by Stacy Matthews Branch, DVM, PhD posted in cd 34 stem cells, CD34, heart disease, Stem Cells

0 Comments

Studying the biological processes that lead to the development of heart disease is essential in the study of preventive and therapeutic approaches to combat the illness.

One in every four deaths in the US is due to heart disease, and the most common type is coronary heart disease caused by arteriosclerosis, a hardening and thickening of the arteries. Studying the biological processes that lead to the development of arterial disease is essential in the study of preventive and therapeutic approaches to combat cardiovascular disease. In vitro methods important for studying disease mechanisms are challenging because explanted endothelial cells can lose their distinctive characteristics.

Read More

Progress in Sickle Cell Cure Research

Mar 26, 2018 10:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in cd 34 stem cells, CD34, disease-state products, sickle cell disease

0 Comments

The findings of a new study on sickle cell disease may lead to a new era in the approach to treatment.

Sickle cell disease (often referred to as sickle cell anemia) is a group of blood disorders in which the blood cells have an abnormal sickle shape instead of the biconcave disk shape. The sickle-shaped cells have a shorter life span (leading to anemia), but they also block normal blood flow leading to pain and organ dysfunction. There is no cure, and treatments that exist are aimed to control symptoms and related complications.

Read More

Therapeutic Gene Editing in CD34+ Stem Cells from Patients with Fanconi Anemia

Nov 8, 2017 3:38:25 PM / by Stacy Matthews Branch, DVM, PhD posted in cd 34 stem cells, CD34, stem cell gene therapy, Stem Cells

0 Comments

Gene (or genome) editing refers to various technologies that are used to alter genetic material. This technology is used as a new means to treat diseases including genetic disorders. Fanconi anemia is an inherited disease that affects bone marrow leading to decreased production of all blood cell types. In general, editing of CD34+ (hematopoietic) stem cells have proven more difficult than for fibroblasts or embryonic stem cells. Some advances have been achieved in this regard; however, the efficiency of gene editing for CD34+ stem cells remains less than that possible with lentiviral vectors.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts